Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

GEVO vs AMTX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GEVO
Gevo, Inc.

Chemicals - Specialty

Basic MaterialsNASDAQ • US
Market Cap$497M
5Y Perf.+57.4%
AMTX
Aemetis, Inc.

Oil & Gas Refining & Marketing

EnergyNASDAQ • US
Market Cap$221M
5Y Perf.+290.0%

GEVO vs AMTX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GEVO logoGEVO
AMTX logoAMTX
IndustryChemicals - SpecialtyOil & Gas Refining & Marketing
Market Cap$497M$221M
Revenue (TTM)$161M$198M
Net Income (TTM)$1M$-77M
Gross Margin49.9%-0.4%
Operating Margin-12.5%-18.8%
Total Debt$3M$318M
Cash & Equiv.$1M$5M

GEVO vs AMTXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GEVO
AMTX
StockMay 20May 26Return
Gevo, Inc. (GEVO)100157.4+57.4%
Aemetis, Inc. (AMTX)100390.0+290.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: GEVO vs AMTX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GEVO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aemetis, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
GEVO
Gevo, Inc.
The Growth Play

GEVO carries the broadest edge in this set and is the clearest fit for growth exposure.

  • Rev growth 8.5%, EPS growth 58.8%, 3Y rev CAGR 415.1%
  • 8.5% revenue growth vs AMTX's -22.3%
  • 0.8% margin vs AMTX's -39.0%
Best for: growth exposure
AMTX
Aemetis, Inc.
The Income Pick

AMTX is the clearest fit if your priority is income & stability and long-term compounding.

  • beta 1.46
  • 12.1% 10Y total return vs GEVO's -98.4%
  • Lower volatility, beta 1.46, current ratio 0.07x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthGEVO logoGEVO8.5% revenue growth vs AMTX's -22.3%
Quality / MarginsGEVO logoGEVO0.8% margin vs AMTX's -39.0%
Stability / SafetyAMTX logoAMTXBeta 1.46 vs GEVO's 1.64
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)AMTX logoAMTX+159.2% vs GEVO's +101.0%
Efficiency (ROA)GEVO logoGEVO0.2% ROA vs AMTX's -31.3%, ROIC -3.6% vs -70.3%

GEVO vs AMTX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GEVOGevo, Inc.
FY 2025
Ethanol
95.6%$105M
Hydrocarbon
4.4%$5M
AMTXAemetis, Inc.
FY 2025
Ethanol Sales
79.4%$116M
Wet Distiller's Grains Sales
20.6%$30M

GEVO vs AMTX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGEVOLAGGINGAMTX

Income & Cash Flow (Last 12 Months)

GEVO leads this category, winning 4 of 6 comparable metrics.

AMTX and GEVO operate at a comparable scale, with $198M and $161M in trailing revenue. GEVO is the more profitable business, keeping 0.8% of every revenue dollar as net income compared to AMTX's -39.0%. On growth, GEVO holds the edge at +7.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
RevenueTrailing 12 months$161M$198M
EBITDAEarnings before interest/tax$5M-$28M
Net IncomeAfter-tax profit$1M-$77M
Free Cash FlowCash after capex-$43M-$23M
Gross MarginGross profit ÷ Revenue+49.9%-0.4%
Operating MarginEBIT ÷ Revenue-12.5%-18.8%
Net MarginNet income ÷ Revenue+0.8%-39.0%
FCF MarginFCF ÷ Revenue-27.0%-11.5%
Rev. Growth (YoY)Latest quarter vs prior year+7.0%-7.9%
EPS Growth (YoY)Latest quarter vs prior year+66.8%+77.5%
GEVO leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — GEVO and AMTX each lead in 1 of 2 comparable metrics.
MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
Market CapShares × price$497M$221M
Enterprise ValueMkt cap + debt − cash$499M$534M
Trailing P/EPrice ÷ TTM EPS-14.64x-2.53x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple97.58x
Price / SalesMarket cap ÷ Revenue3.10x1.06x
Price / BookPrice ÷ Book value/share1.02x
Price / FCFMarket cap ÷ FCF
Evenly matched — GEVO and AMTX each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

GEVO leads this category, winning 6 of 7 comparable metrics.

On the Piotroski fundamental quality scale (0–9), AMTX scores 4/9 vs GEVO's 2/9, reflecting mixed financial health.

MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
ROE (TTM)Return on equity+0.3%
ROA (TTM)Return on assets+0.2%-31.3%
ROICReturn on invested capital-3.6%-70.3%
ROCEReturn on capital employed-9.0%-19.0%
Piotroski ScoreFundamental quality 0–924
Debt / EquityFinancial leverage0.01x
Net DebtTotal debt minus cash$2M$313M
Cash & Equiv.Liquid assets$1M$5M
Total DebtShort + long-term debt$3M$318M
Interest CoverageEBIT ÷ Interest expense-0.59x-0.61x
GEVO leads this category, winning 6 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — GEVO and AMTX each lead in 3 of 6 comparable metrics.

A $10,000 investment in GEVO five years ago would be worth $3,516 today (with dividends reinvested), compared to $1,952 for AMTX. Over the past 12 months, AMTX leads with a +159.2% total return vs GEVO's +101.0%. The 3-year compound annual growth rate (CAGR) favors GEVO at 18.6% vs AMTX's 12.6% — a key indicator of consistent wealth creation.

MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
YTD ReturnYear-to-date-0.5%+103.8%
1-Year ReturnPast 12 months+101.0%+159.2%
3-Year ReturnCumulative with dividends+66.7%+42.7%
5-Year ReturnCumulative with dividends-64.8%-80.5%
10-Year ReturnCumulative with dividends-98.4%+12.1%
CAGR (3Y)Annualised 3-year return+18.6%+12.6%
Evenly matched — GEVO and AMTX each lead in 3 of 6 comparable metrics.

Risk & Volatility

AMTX leads this category, winning 2 of 2 comparable metrics.

AMTX is the less volatile stock with a 1.46 beta — it tends to amplify market swings less than GEVO's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMTX currently trades 85.3% from its 52-week high vs GEVO's 69.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
Beta (5Y)Sensitivity to S&P 5001.64x1.46x
52-Week HighHighest price in past year$2.97$3.80
52-Week LowLowest price in past year$1.01$1.22
% of 52W HighCurrent price vs 52-week peak+69.0%+85.3%
RSI (14)Momentum oscillator 0–10056.270.0
Avg Volume (50D)Average daily shares traded4.4M1.7M
AMTX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates GEVO as "Buy" and AMTX as "Buy". Consensus price targets imply 70.7% upside for GEVO (target: $4) vs -46.0% for AMTX (target: $2).

MetricGEVO logoGEVOGevo, Inc.AMTX logoAMTXAemetis, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$3.50$1.75
# AnalystsCovering analysts147
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GEVO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AMTX leads in 1 (Risk & Volatility). 2 tied.

Best OverallGevo, Inc. (GEVO)Leads 2 of 6 categories
Loading custom metrics...

GEVO vs AMTX: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is GEVO or AMTX a better buy right now?

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -22. 3% for Aemetis, Inc. (AMTX). Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — GEVO or AMTX?

Over the past 5 years, Gevo, Inc.

(GEVO) delivered a total return of -64. 8%, compared to -80. 5% for Aemetis, Inc. (AMTX). Over 10 years, the gap is even starker: AMTX returned +31. 1% versus GEVO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — GEVO or AMTX?

By beta (market sensitivity over 5 years), Aemetis, Inc.

(AMTX) is the lower-risk stock at 1. 46β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 13% more volatile than AMTX relative to the S&P 500.

04

Which is growing faster — GEVO or AMTX?

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -22. 3% for Aemetis, Inc. (AMTX). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to 33. 0% for Aemetis, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — GEVO or AMTX?

Gevo, Inc.

(GEVO) is the more profitable company, earning 0. 8% net margin versus -37. 0% for Aemetis, Inc. — meaning it keeps 0. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -12. 6% versus -17. 9% for AMTX. At the gross margin level — before operating expenses — GEVO leads at 49. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — GEVO or AMTX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is GEVO or AMTX better for a retirement portfolio?

For long-horizon retirement investors, Aemetis, Inc.

(AMTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMTX: +31. 1%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between GEVO and AMTX?

These companies operate in different sectors (GEVO (Basic Materials) and AMTX (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GEVO is a small-cap high-growth stock; AMTX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

GEVO

High-Growth Disruptor

  • Sector: Basic Materials
  • Market Cap > $100B
  • Revenue Growth > 347%
  • Gross Margin > 29%
Run This Screen
Stocks Like

AMTX

Quality Business

  • Sector: Energy
  • Market Cap > $100B
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform GEVO and AMTX on the metrics below

Revenue Growth>
%
(GEVO: 695.6% · AMTX: -7.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.